Patents by Inventor Brigitte Assouline
Brigitte Assouline has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416398Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.Type: ApplicationFiled: May 22, 2023Publication date: December 28, 2023Inventors: Stéphane BIRKLE, Julien FLEURENCE, Sébastien FARAJ, Jean-Marc LE DOUSSAL, Denis COCHONNEAU, Mickaël TERME, Brigitte ASSOULINE
-
Patent number: 11697689Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.Type: GrantFiled: December 5, 2017Date of Patent: July 11, 2023Assignees: OGD2 PHARMA, NANTES UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE CANCEROLOGIE DE L'OUESTInventors: Stéphane Birkle, Julien Fleurence, Sébastien Faraj, Jean-Marc Le Doussal, Denis Cochonneau, Mickaël Terme, Brigitte Assouline
-
Publication number: 20230148349Abstract: Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id n°112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id n°76; and its use in diagnostics and therapy.Type: ApplicationFiled: August 3, 2022Publication date: May 11, 2023Inventors: Mickaël TERME, Jean-Marc LE DOUSSAL, Mylene DORVILLIUS, Brigitte ASSOULINE
-
Patent number: 11440968Abstract: Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.Type: GrantFiled: July 17, 2017Date of Patent: September 13, 2022Assignee: OGD2 PHARMAInventors: Mickaël Terme, Jean-Marc Le Doussal, Mylene Dorvillius, Brigitte Assouline
-
Publication number: 20190375853Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.Type: ApplicationFiled: December 5, 2017Publication date: December 12, 2019Inventors: Stéphane BIRKLE, Julien FLEURENCE, Sébastien FARAJ, Jean-Marc LE DOUSSAL, Denis COCHONNEAU, Mickaël TERME, Brigitte ASSOULINE
-
Publication number: 20190233537Abstract: Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.Type: ApplicationFiled: July 17, 2017Publication date: August 1, 2019Applicant: OGD2 PHARMAInventors: Mickaël TERME, Jean-Marc LE DOUSSAL, Mylene DORVILLIUS, Brigitte ASSOULINE
-
Publication number: 20140377218Abstract: The invention relates to the use of Interleukin-7 (IL-7), for treating hepatitis C in a patient infected with hepatitis C virus, wherein said patient has been treated or is being treated with an antiviral agent or a combination of antiviral agents that reduces viral load.Type: ApplicationFiled: August 2, 2012Publication date: December 25, 2014Applicant: CYTHERISInventors: Michel Morre, Brigitte Assouline, Therese Croughs, Pierre Demol, Stephanie Beq
-
Patent number: 8153114Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: GrantFiled: August 24, 2011Date of Patent: April 10, 2012Assignee: CytherisInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Publication number: 20120016104Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: ApplicationFiled: August 24, 2011Publication date: January 19, 2012Applicant: CYTHERISInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Patent number: 8034327Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: GrantFiled: February 24, 2010Date of Patent: October 11, 2011Assignee: CytherisInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Publication number: 20100196312Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: ApplicationFiled: February 24, 2010Publication date: August 5, 2010Applicant: CYTHERISInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Patent number: 7708985Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: GrantFiled: July 19, 2006Date of Patent: May 4, 2010Assignee: CYTHERISInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Patent number: 7585947Abstract: The present invention relates, generally, to the fields of immunology and molecular biology. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compositions comprising the same, their preparation and uses. The invention also discloses methods to characterize the impurity profile of a r-hIL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides.Type: GrantFiled: August 6, 2003Date of Patent: September 8, 2009Assignee: CytherisInventors: Michel Christian Morre, Brigitte Assouline, Pierre Cortez, Anne Gregoire
-
Publication number: 20080206190Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.Type: ApplicationFiled: July 19, 2006Publication date: August 28, 2008Applicant: CYTHERISInventors: Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
-
Publication number: 20050249701Abstract: The present invention relates, generally, to the fields of immunology and molecular biology. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compositions comprising the same, their preparation and uses. The invention also discloses methods to characterize the impurity profile of a r-hIL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides.Type: ApplicationFiled: August 6, 2003Publication date: November 10, 2005Inventors: Michel Morre, Brigitte Assouline, Pierre Cortez, Anne Gregoire